Decades ago Intel Co-Founder Gordon Moore observed that the density, degree of miniaturization, and ultimately the performance of electronic components, was doubling every two years.
This exponential increase of electronics performance, dubbed Moore’s Law, has been followed so far and resulted in a spectacular growth of electronics, communications and computing over the last few decades.
However, indications that Moore’s Law could be slowing down as shrinking electronics approaches fundamental size limits have thrown the electronics and computing industries into panic. How could Apple, for example, keep packing more and more features into new iPhones if Moore’s Law stops?
Enter Lawrence Berkeley National Laboratory (aka Berkeley Lab). On October 6 Berkeley Lab announced that engineers in a Berkeley-led research team have broken major barrier in transistor size by creating a gate only one nanometer (one billionth of a meter) long, which represents a five times improvement over the five nanometers that were thought to represent a theoretical limit.
The results are reported in Science with the title “MoS2 transistors with 1-nanometer gate lengths.”
“[Engineers] knew that the laws of physics had set a 5-nanometer threshold on the size of transistor gates among conventional semiconductors, about one-quarter the size of high-end 20-nanometer-gate transistors now on the market,” notes the Berkeley Lab press release.
Some laws are made to be broken, or at least challenged.
The development could be key to keeping Moore’s Law alive, enabling the increased performance of our laptops, mobile phones, televisions, and other electronics.
“We made the smallest transistor reported to date,” says research team leader Ali Javey. “The gate length is considered a defining dimension of the transistor. We demonstrated a 1-nanometer-gate transistor, showing that with the choice of proper materials, there is a lot more room to shrink our electronics.”
“Here, we demonstrate 1D gated, 2D semiconductor field-effect transistors (1D2D-FETs) with a single-walled carbon nanotube (SWCNT) gate, a MoS2 channel, and physical gate lengths of ~1 nm,” reads the Science paper.
New Materials With Immense Potential For Future Electronics
The researchers achieved this breakthrough by using molybdenum disulfide (MoS2), a material with “immense potential” for applications in LEDs, lasers, nanoscale transistors, solar cells, and more.
Sujay Desai, a graduate student in Javey’s lab, explains that the semiconductor industry has long assumed that any gate below 5 nanometers wouldn’t work, so anything below that was not even considered. “This research shows that sub-5-nanometer gates should not be discounted,” says Desai. “Industry has been squeezing every last bit of capability out of silicon. By changing the material from silicon to MoS2, we can make a transistor with a gate that is just 1 nanometer in length, and operate it like a switch.”
Besides the MoS2 substrate, the engineers used a single-walled carbon nanotube to construct the one-nanometer gate, and verified that the MoS2 transistor with the carbon-nanotube gate effectively controlled the flow of electrons.
Carbon nanotubes offer many promising features for future electronics. For example, a nanotube’s ultra-small dimension permits rapidly varying the current that flows through. In September, Hacked reported that University of Wisconsin–Madison materials engineers created carbon nanotube transistors that, for the first time, outperformed state-of-the-art silicon transistors, a breakthrough that points the way to future high-performance nanotube electronics. Earlier this year, Nantero announced the use of carbon nanotubes for storage that can be fabricated on DRAM, flash, and system production lines.
“This work demonstrated the shortest transistor ever,” concludes Javey. “However, it’s a proof of concept. We have not yet packed these transistors onto a chip, and we haven’t done this billions of times over. We also have not developed self-aligned fabrication schemes for reducing parasitic resistances in the device. But this work is important to show that we are no longer limited to a 5-nanometer gate for our transistors.”
Moore’s Law can continue a while longer by proper engineering of the semiconductor material and device architecture.”
Images from iStock and Sujay Desai/UC Berkeley.
Biotech Dominates July Penny Stock Picks
July brings new opportunities to trade penny stocks, according to the Investopedia top 10 penny stocks to watch. Biotechnology stocks in particular are poised for a breakout. Biotechnology funds broke out of the long-term basing pattern in June, forcing rotational buying pressure, which bodes well for the low-priced sub-sector, with many penny stocks ready to hit multi-year highs.
At the same time, the tech sector is getting sold with equal force in a profit-taking exercise that could deliver a period of under-performance for the sector’s lower-priced issues.
June’s biotechnology picks drew strong buying interest, led by ImmunoGen, Inc.’s 48% advance to a 52-week high. Small China stocks also posted strength, as China Commercial Credit, Inc. gained close to 35%. China Commercial Credit and June’s three biotech picks return to the July top penny stock list, joined by six new penny stocks.
1. ImmunoGen Inc. (IMGN)
ImmunoGen, a provider of antibody-drug conjugates (ADCs) for the treatment of cancer, jumped from number four in June to the top spot in July.
The stock posted a 12-year high at $20.25 in 2013 and sold off to $5.34 in December 2014. A recovery in 2015 stalled less than a point below the prior peak, creating a decline that continued into an 18-year low at $1.51 in November 2016.
Buyers took over in 2017, generating an uptick that reversed at the 2014 resistance approximately three weeks ago. In June, the stock broke out and made the top 10 list for the first time. It could end up in the $8.00 to $10.00 price zone.
ImmunoGen creates targeted cancer therapeutics using its proprietary ADC technology. The company’s candidate, mirvetuximab soravtansine, is in a Phase 3 trial for an ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease.
The technology is used in Roche’s Kadcyla, in three other clinical-stage ImmunoGen product candidates, and in programs in development by Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
2. China Commercial Credit, Inc. (CCCR)
China Commercial Credit Inc. (CCCR), which provides business loans and loan guarantee services to small-to-medium enterprises (SMEs), farmers and individuals in China’s Jiangsu Province, jumped from number five in June to second place in July.
The company went public on the U.S. exchanges at $6.50 in August 2013.
The stock experienced a downtrend that bottomed out at 25 cents in February 2016 and began an upward trend that stalled at $3.20 in September. The stock hit a higher low in March 2017 before recovering, testing the 2016 high. A breakout should bring broad buying interest that could support a continued upside that could double the price by year’s end.
The company was founded in 2008 and provides business loans and loan guarantee services to small-to-medium enterprises, farmers and individuals in China’s Jiangsu Province.
3. CymaBay Therapeutics, Inc. (CBAY)
CymaBay Therapeutics Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases, returns from the June list, where it ranked number 9. The stock rallied to an all-time high at $13.78 in February 2015, then suffered a steep downtrend that continued into the first quarter of 2016. The stock then dropped to an all-time low at 82 cents before bouncing to $3.04 in April, a yearly high, ahead of a pullback that continued into the November low at $1.15.
The stock broke above the 2016 high in February 2017, reaching a two-year high at $4.81.
Net loss for the 2017 first quarter was $5.4 million, or ($0.20) per diluted share, compared to $6.8 million, or ($0.29) per diluted share in the first quarter of 2016. Net loss in the 2017 first quarter was $1.4 million lower compared to the prior year period, primarily due to the recognition of collaboration revenue in 2017.
The rally has now reached a two-year high, attracting buying interest that could move into double digits.
4. Peiris Pharmaceuticals, Inc. (PIRS)
Pieris Pharmaceuticals Inc., a, clinical-stage biotechnology company committed to providing solutions for oncology, respiratory disease and other therapeutic areas, moved from June’s 7th spot to July’s 4th spot. The stock launched on the OTC market in 2014, trading between $2.00 and $4.25 before falling to $1.26 in January 2016. It ground sideways through November, then tested the first-quarter low ahead of a January 2017 breakaway gap that has drawn steady buying interest. The rally gathered momentum in early May after announcing a partnership with AstraZeneca PLC and is currently testing the 2015 high, the all-time high.
The company’s product includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma as well as a half-life-optimized Anticalin protein to treat anemia. Anticalin proteins, proprietary to Pieris, are a class of therapeutics validated in the clinic and partnerships with pharmaceutical companies. Anticalin is a registered trademark of Pieris.
5. 22nd Century Group, Inc. (XXII)
22nd Century Group, Inc. (XXII), a plant biotechnology company that is a provider of tobacco harm reduction and development of proprietary hemp/cannabis strains, broke out above multi-year resistance near $1.50 in 2013, rallying to a record high a few months later at $6.36. The stock then began a persistent decline through August 2015 before finding support at 56 cents, followed by a bounce to $1.75.
The stock has traded within those boundaries for 22-months, bouncing at support three times and reversing at resistance in equal measure. The price returned to that level a fourth time, improving odds for a breakout that could double the price in the year’s second half.
22nd Century Group is a plant biotechnology company focused on genetic engineering and plant breeding that allows the increase or decrease of the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants. The company’s main goal in tobacco is to reduce the harm caused by smoking. The main goal in cannabis is to develop proprietary hemp/cannabis strains for new medicines and agricultural crops.
The stock last month joined the Russell Microcap Index, when FTSE Russell reconstituted its U.S. and global equity indexes. Membership in the Russell Microcap Index means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
6. Corindus Vascular Robotics, Inc. (CVRS)
Corindus Vascular Robotics, Inc. (CVRS), a developer of precision vascular robotics, returned to the national market in 2015 following a trading halt, topping out around $4.50 and starting a decline that continued to reach new lows in January 2017 when it bottomed at around 40 cents. Since that time, the price activity has been constructive, with high volume rally bursts moving the stock into 2016 resistance at $1.75. The bullish behavior has created a cup and handle basing pattern that points to an uptrend into the 2015 high following a breakout.
Revenue for the first quarter of 2017 was $0.8 million compared to $1.1 million for the same period in the prior year. The decrease is due mainly to the deferral of system revenue associated with a future obligation to upgrade multiple customer units from the company’s CorPath 200 System to the CorPath GRX System.
The company installed three new CorPath Systems in the first quarter of 2017, increasing its total installed base to 48 CorPath Systems.
Gross loss was $1.1 million for the 2017 first quarter, compared to a gross profit of $0.03 million for the 2016 first quarter. The cost of revenues for the first 2017 quarter continued to include the effect of under-utilization of production facilities and the cost of CorPath GRX System upgrades that installed pursuant to pre-existing contractual arrangements.
The company continues to expect the full year 2017 revenue to be in the range of $13.
7. RADA Electronic Industries, Ltd. (RADA)
RADA Electronic Industries, Ltd. (RADA), a defense electronics system of advanced electronic systems for airborne and land applications, fell into a multi-decade decline after it joined the Nasdaq in the 1990s. The stock ground out a series of lower highs and lows through January 2016’s all-time 54-cent low.
The stock spent 16 months moving sideways in a narrow basing pattern before turning higher in May 2017 and rallying back to 2016 resistance at $1.78. The bullish activity completed a cup and handle breakout pattern that could point to a fast rally into the August 2015 gap between $3.70 and $2.50.
Revenues totaled $4.7 million in the 2017 first quarter, up 91% compared to revenues of $2.5 million in the first quarter of 2016.
Gross profit totaled $1.7 million in the first 2017 quarter of 2017, a gross margin of 35.7%, compared to gross profit of $6,000 (gross margin of 0.2%) in the 2016 first quarter.
Operating income was $0.4 million in the first 2017 quarter compared to an operating loss of $1 million in the 2016 first quarter.
Net income attributable to RADA’s shareholders in the 2017 first quarter was $0.4 million, $0.02 per share, versus a net loss of $1.8 million, or $0.23 per share, in the 2016 first quarter.
8. ChromaDex, Corp. (CDXC)
ChromaDex, Corp. (CDXC), a provider of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition and pharmaceutical products, went public in April 2016 at $4.70. The stock rallied to an all-time high at $6.18 in May, then fell one month later to $2.46 in a single session, eventually posting a lower December low. It tested that support level in April 2017, then turned sharply higher, now testing 2017 resistance at $3.80. A breakout could point to a significant upside, taking the stock back to last year’s high.
For the first quarter of 2017, ChromaDex reported net sales of $4.4 million, a decrease of 39% compared to the same period of 2016, due mainly to decreased sales in its ingredients business segment, as a result of dropping its largest customer for fiscal year 2016. The ingredients segment created net sales of $2.1 million for Q1 2017, a decline of 55%, compared to the same 2016 period.
The net loss attributable to common stock holders for Q1 2017 was $1.9 million or ($0.05) per share versus a net income of $0.3 million or $0.01 per share for Q1 2016.
In May, the company announced the closing of the $16.4 million second tranche of the strategic investment of up to $25 million led by Hong Kong business leader Li Ka-shing.
Li Ka-shing has invested in many innovative companies in the last decade, including Facebook, Spotify, DeepMind, Siri, Impossible Foods and Modern Meadow. The new investment will support future ChromaDex developments in the global marketplace.
The $16.4 million second tranche follows an initial $3.5 million tranche that closed on April 27, 2017.
9. Safe Bulkers, Inc. (SB)
Safe Bulkers, Inc. (SB), a player in the hot and cold dry bulk shipping sector, topped out at $11.48 in March 2014, then entered a downtrend reaching an all-time low at 30 cents in January 2016. A recovery wave in November stalled at $2.38, followed by sideways action that has completed a small-scale cup and handle breakout pattern. A buying spike over $2.60 can be expected to set the upside into action, supporting a rally that could surpass $5.00.
The company declared a cash dividend of $0.50 per share on its 8.00% Series B, Series C and Series D Cumulative Redeemable Perpetual Preferred Shares for the period from April 30, 2017 to July 29, 2017.
This is the 16th consecutive cash dividend declared on the company’s Series B Preferred Shares, the 13th cash dividend declared on its Series C Preferred Shares and the 12th cash dividend declared on its Series D Preferred Shares since their respective commencement of trading on the New York Stock Exchange.
10. Ballard Power Systems, Inc. (BLDP)
Ballard Power Systems, Inc. (BLDP) is a provider of clean energy products that reduce customer costs and risks, and helps customers solve challenges in their fuel cell programs. The stock reached an all-time high at $144.95 in 2000 before falling into a downtrend lasting more than 12 years, sending the stock to an all-time low at 56 cents. A 2013 upward trend continued through 2014, hitting an 8-year high at $8.38, followed by a correction that’s now returned to 2015 resistance at $3.10. A breakout could catch fire, pushing the stock to a test of its 2014 high.
Total revenue was $22.7 million in the quarter, an increase of 39% from growth in both power products and technology solutions.
Gross margin was 42% in the quarter, an improvement of 22 points due to a shift in product mix toward higher margin technology solutions and heavy duty motive for the China market, including the establishment of a production line in Yunfu, China for the manufacture and assembly of FCvelocity-9SSL fuel cell stacks.
Cash operating costs were $10 million in the quarter, a 6% increase due to higher research and product development expenditures as well as a stronger Canadian dollar relative to the U.S. dollar, since a significant amount of cost is denominated in Canadian dollars.
Low-priced biotech stocks have risen following a long slumber, with steady buying interest likely to continue. This group should offer a variety of profitable penny stock plays during the quiet summer trading season, while low-priced stocks in other sectors move into narrow trading ranges.
Featured image from Shutterstock.
Drones Are a Next-Generation Computing Platform, Says Intel
Intel announced the first Intel drone designed specifically for light shows: the Intel Shooting Star drone. With this drone, the company plans to demonstrate that drone light shows can redefine entertainment and create amazing new experiences in the night sky.
Chinese Physicists Achieve Record-Breaking Quantum Cryptography Breakthrough
Researchers at the University of Science and Technology of China and other Chinese labs, with the collaboration of a lab in the US, have implemented a secure quantum protocol known as Measurement-Device-Independent Quantum Key Distribution (MDIQKD), suitable for practical networks and devices, over a distance of 404 km. The breakthrough, which doubles the previous MDIQKD record, opens the door to secure wide area quantum communication networks.
- Trade Recommendation: GBPJPY November 19, 2017
- ICO Analysis: Experty November 19, 2017
- Trade Recommendation: Enjin (ENJ) November 19, 2017
- Bitcoin IRA: How to Save for Retirement Using Cryptocurrency November 19, 2017
- Long-Term Cryptocurrency Analysis: Bitcoin Flirts with $8000 as Altcoin Bull Persists November 18, 2017
- Trade Recommendation: Zcash November 18, 2017
- Trade Recommendation: Bitcoin November 18, 2017
- Segwit2x: The Hard Fork That Failed to Activate November 18, 2017
- Hacked.com Weekly Webinar Series: Nov. 17 Edition November 18, 2017
- NEO Is Crushing It Today November 18, 2017
A part of CCN
Analysis1 week ago
Long-Term Cryptocurrency Analysis: Bitcoin Enters Correction as Altcoins Break Out
Cryptocurrencies5 days ago
Trade Recommendation: Bitcoin Cash
Altcoins1 week ago
Bitcoin Cash (BCH) and Bitcoin (BTC) Showdown – Let the Fight Begin
Cryptocurrencies1 week ago
Trade Recommendation: Bitcoin Cash
Cryptocurrencies1 week ago
Trade Recommendation: Litecoin
Analysis1 week ago
Technical Analysis: Bitcoin Breaks Below $7000, Altcoins Pull Back, As Bitcoin Cash Jumps
Cryptocurrencies6 days ago
Trade Recommendation: Ethereum Classic
Cryptocurrencies1 week ago
Trade Recommendation: Ethereum Classic